We chose to use tucidinostat (chidamide), a selective inhibitor of class I HDAC1−HDAC3 and class IIb HDAC10, which has been clinically approved for peripheral T-cell lymphoma and adult T-cell leukemia-lymphoma33,34. This evidence concerns the gene HDAC10 and adult T-cell leukemia/lymphoma.